OVOCA BIO PLC |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.01 EUR | 0.00% |
|
0.00% | 0.00% |
| 07-15 | Jet2 chair buys; Ovoca Bio's old CEO sells to new | AN |
| 07-15 | Ovoca Bio CEO to Resign in August; Successor Named | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Ovoca Bio Plc is a biopharmaceutical company specialized in the development and manufacturing of peptides for the treatment of female sexual dysfunction.
At the end of 2022, the Group had a product in phase III clinical development (Orenetide).
Calendar
2024-09-25
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 890K | |
| +20.63% | 127B | |
| +25.36% | 27.67B | |
| -20.17% | 20.33B | |
| -16.94% | 16.79B | |
| -18.07% | 15.63B | |
| -47.70% | 14.65B | |
| +11.92% | 14.84B | |
| +58.32% | 14.43B | |
| +149.98% | 12.49B |
- Stock Market
- Equities
- OVXA Stock
- News Ovoca Bio plc
- Ovoca Bio CEO to Resign in August; Successor Named
